Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Igalmi in Agitated Schizophrenic or Bipolar Patients
NCT06041646Phase 4Completed
- Sponsor
- BioXcel Therapeutics, Inc.
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dexmedetomidine in agitation, sponsored by BioXcel Therapeutics, Inc.. Started Oct 2023; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
agitation
Beyond the preview
Go deeper on NCT06041646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041646.